Canada-based Titan Medical has recently commenced tissue testing that was successful in assessing and measuring the functionality of the SPORT (single port orifice robotic technology) surgical system.
The company will perform a sequence of tests during the tissue testing and will make refinements and improvements for the SPORT surgical system after each test for making a finalized fully-functional surgical system.
Tissue testing makes up the first major milestone on Titan Medical’s pathway to commercialization.
Titan Medical has implemented protocols in the first two tests in the last two weeks and has successfully attained the goals.
The company has planned two more tests by December 2013.
It will conduct iterative testing and fine tuning of all the components of the SPORT surgical system during the next nine months.
Titan Medical director of clinical affairs Dr Dennis Fowler is leading the tissue testing.
Dr Fowler is working in cooperation with the Clinical and Regulatory department of Ximedica, Titan Medical’s development partner of record, in solidifying the company’s regulatory strategy for obtaining the US Food and Drug Administration (FDA) marketing approval and for obtaining CE Mark approval from the EU for the SPORT surgical system.
"The objective of tissue testing is to either confirm the performance of the SPORT™ Surgical System or identify areas of performance that require fine tuning. To date, the engineers and clinical consultants have been extremely pleased with the technology and the testing results.
"I am delighted with the progress that we are making.
"To date, the engineers and clinical consultants have been extremely pleased with the technology and the testing results. I am delighted with the progress that we are making," Dr Fowler added.
Titan Medical CEO John Hargrove noted the company is continuing to meet out milestones and remain on track for commercialization in 2015.